Location History:
- Brussles, BE (2017)
- Brussels, BE (2017 - 2020)
- Munich, DE (2021)
Company Filing History:
Years Active: 2017-2021
Title: Michel Janicot: Innovator in Ophthalmic Treatments
Introduction
Michel Janicot is a prominent inventor based in Brussels, Belgium. He has made significant contributions to the field of ophthalmology through his innovative research and development of oligonucleotides for treating various ophthalmic diseases. With a total of six patents to his name, Janicot continues to push the boundaries of medical science.
Latest Patents
One of Janicot's latest patents involves a TGF-beta oligonucleotide designed for use in the treatment of ophthalmic diseases. This invention focuses on an oligonucleotide that includes a nucleic acid sequence of SEQ ID No. 1 or parts thereof. The oligonucleotide is modified at the 3'-end and/or 5'-end to reduce or inhibit scarring, fibrotic closure of the trabeculectomy canal, and epithelial-to-mesenchymal transition of the trabecular meshwork. Additionally, it aims to provide protective activity for the optic nerve. Another significant patent pertains to modified TGF-beta oligonucleotides, which consist of 10 to 20 nucleotides from selected regions of the TGF-beta1, TGF-beta2, or TGF-beta3 nucleic acid sequences. These oligonucleotides are utilized in the prevention and treatment of various conditions, including tumors, immunologic diseases, and glaucoma.
Career Highlights
Michel Janicot is currently associated with Isarna Therapeutics GmbH, where he applies his expertise in developing innovative therapeutic solutions. His work has been instrumental in advancing the understanding and treatment of complex ophthalmic conditions.
Collaborations
Janicot collaborates with notable colleagues such as Frank Jaschinski and Eugen Uhlmann, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Michel Janicot's contributions to the field of ophthalmology through his patents and collaborative efforts highlight his role as a leading inventor. His work continues to pave the way for new treatments that can significantly improve patient outcomes in ophthalmic care.